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ABSTRACT 
Background: HIV/AIDS has already become one of the world's major health issues taking its toll on 
millions of lives each year. Developing an HIV vaccine with excellent efficacy has become a global 
urgency that must be addressed immediately. Recently, researchers have successfully developed a 
more self-like molecule which is a fusion protein between human CD4 domains and immunoglobulin 
G (IgG) Fc with a CCR5-mimetic sulfopeptide in the carboxy terminus. This molecule, eCD4-Ig, 
targets only the conserved regions of HIV Env and thus demonstrated the most remarkable potency 
and breadth so far. By using adeno-associated virus (AAV) vector, eCD4-Ig’s long-term expression in 
vivo can be achieved. Objectives: Evaluate the efficacy of AAV-eCD4-Ig as both preventive and 
therapeutic vaccine for HIV/AIDS infection. Methods: A systematic literature study was conducted 
with the database in PubMed, ScienceDirect, and Proquest. No time and language restriction were 
applied. Discussion: This review shows that eCD4-Ig eliminates HIV-infected cells through 
neutralization and antibody-dependent cell-mediated cytotoxicity (ADCC). Moreover, eCD4-Ig is also 
capable of preventing HIV infection in vivo. Delivered with AAV, eCD4-Ig is maintained stably at 
both protective and therapeutic levels, as well as gives robust protection for rhesus macaques for 
almost a year long through a single injection. Conclusion: This study offers evidences that AAV-
eCD4-Ig appears to have the potential to be an effective vaccine to prevent HIV infection. 
Keywords: AAV, AIDS, eCD4-Ig, HIV, vaccine 
ABSTRAK 
Latar Belakang: Pengembangan vaksin HIV yang efektif menjadi sangat penting mengingat tingginya 
angka kematian yang ditimbulkan oleh HIV/AIDS. Beberapa tahun terakhir, peneliti berhasil 
menemukan sebuah molekul yang tersusun atas domain CD4 manusia, immunoglobulin G (IgG) Fc, 
dan sulfopeptida yang menyerupai CCR5. Molekul yang dinamakan eCD4-Ig ini menargetkan area 
konservatif dari HIV Env sehingga berpotensi untuk menjadi vaksin HIV yang efektif. Ekspresi eCD4-
Ig akan dipertahankan menggunakan Adeno-associated Virus Vector (AAV). Tujuan: Evaluasi 
efektivitas AAV-eCD4-Ig sebagai vaksin untuk HIV/AIDS. Metode: Penelitian dilakukan dengan 
melakukan tinjauan pustaka dari beberapa database jurnal, yakni PubMed, ScienceDirect, dan 
Proquest tanpa ada batasan waktu dan bahasa. Pembahasan: eCD4-Ig membunuh sel-sel yang 
terinfeksi HIV melalui proses netralisasi dan antibody-dependent cell-mediated cytotoxicity (ADCC). 
eCD4-Ig juga memberikan perlindungan terhadap infeksi HIV. Ekspresi AAV-eCD4-Ig sangat stabil 
untuk dosis protektif dan terapeutik, sekaligus melindungi rhesus macaques dari infeksi HIV selama 
hampir 1 tahun lamanya hanya dengan sekali injeksi. Kesimpulan: AAV-eCD4-Ig memiliki potensi 
yang menjanjikan untuk menjadi vaksin HIV yang efektif bagi seluruh penderita HIV/AIDS di seluruh 
dunia.  
Kata Kunci: AAV, AIDS, eCD4-Ig, HIV, vaksin 
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Human immunodeficiency virus 
(HIV) is a virus that attacks humans’ 
immune system. This highly contagious 
virus specifically targets the CD4+ T cells 
and later destroys the entire cells colonies. 
If left untreated, the number of CD4+ T 
cells will continue to decline rendering the 
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infection – a condition known as acquired 
immunodeficiency syndrome (AIDS).[1,2]  
HIV/AIDS has become a worldwide 
major health issue. According to World 
Health Organization (WHO) and Joint 
United Nations Programme on HIV/AIDS 
(UNAIDS), there were approximately 37.9 
million people worldwide living with 
HIV/AIDS in 2018.[2,3]  Since the 
beginning of the AIDS epidemic, HIV has 
claimed more than 32 million of lives 
globally.[2] 
For the last few decades, the medicine 
used for treating HIV/AIDS is called 
antiretroviral therapy (ART). It does not 
cure HIV infection, but only suppress viral 
load temporarily.[4-7] In 2018, WHO 
reported that 23.3 million people (62%) 
living with HIV/AIDS are currently 
receiving ART.[2] ART as the current HIV 
therapy is necessary, but not competent 
enough to end the global AIDS epidemic. 
In the early years of the AIDS 
epidemic, immunotherapy against HIV-1 
was developed. Human monoclonal 
antibodies (mAb) appear to shed light on 
HIV/AIDS therapy. Treatment with mAb 
showed a slight improvement than the 
previously used therapies. However, mAbs 
had limited breadth against multiple HIV-1 
strains.[8,9]  
Several years after the discovery of 
mAB, researchers have tried to transfer 
antibodies from the sera of HIV-infected 
subjects to AIDS patients. Unfortunately, 
these antibodies were ineffective against 
the diverse and highly adaptive virus.[5] 
However, studies demonstrated that 20–
50% of chronically HIV-infected 
individuals could produce antibodies that 
target shared epitopes across various 
clades of HIV – later known as broadly 
neutralizing antibodies (bNAbs).[4,5,9,10]  
Since then, multiple bNAbs targeting 
different HIV envelope glycoprotein (Env) 
had been identified. The best ones ever 
found, N6 and 10E8, manage to neutralize 
98% of HIV strains with 50% inhibitory 
concentration (IC50) up to 50 
μg/mL.[5,6,8,9,11] Although seems 
promising, however, developing a potent 
and broad bNAb requires excessive 
mutation of antibody genes.[7] Thus, the 
newly-formed bNAbs are frequently 
subjected to the host’s immune system – 
inducing the formation of anti-drug 
antibodies (ADA) – that further decrease 
their efficacy even more.[7,12-15] 
In order to ensure neutralization of 
HIV, excellent potency and breadth is a 
necessity for developing an effective HIV 
vaccine. At the same time, it should 
maintain a low immunogenicity profile 
when administered to humans. 
Considering this, researchers have begun 
to explore the possibility of molecules 
resembling antibodies that could recognize 
HIV conserved epitopes. Recently, 
researchers have successfully developed a 
fusion protein which functions like an 
antibody. This more self-like molecule is a 
fusion between human CD4 domains and 
immunoglobulin G (IgG) Fc with a CCR5-
mimetic sulfopeptide in the carboxy 
terminus.[11,12,16,17] This molecule, eCD4-
Ig, targets only the conserved regions of 
HIV Env and thus demonstrated the most 
remarkable potency and breadth so far. 
Besides being potent and broad, 
eCD4-Ig’s long-term expression in vivo 
must be maintained at protective and 
therapeutic levels. This response can be 
achieved by using adeno-associated virus 
(AAV) vector. AAV-expressed eCD4-Ig is 
maintained stably for almost a year-long 
through a single injection.[11,12,16] 
Therefore, this study is conducted to 
highlight the efficacy of eCD4-Ig, 
delivered with AAV vector, as both 




Data Sources and Search 
A systematic literature study was 
conducted with the database in PubMed, 
ScienceDirect, and Proquest. No time and 
language restriction were applied. The 
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“eCD4-Ig” AND “HIV” OR “human 
immunodeficiency virus” OR “AIDS” OR 
“acquired immunodeficiency syndrome”. 
The results from the literature search were 
first reviewed by reading the titles and 
abstracts. The relevant studies were further 
checked by reading the full texts and 
assessed for inclusion. Search in electronic 
database yielded 323 studies. Screening 
through titles and abstracts found 32 
articles, 9 of which met the eligibility 
criteria of current study. Search in 
electronic database yielded 323 studies. 
Screening through titles and abstracts 
found 32 articles, 9 of which met the 
eligibility criteria of current study. 
 
Eligibility Criteria 
The following criteria are considered 
for studies’ eligibility: type of studies, 
problem, intervention, comparison, 
outcome (PICO). 
Type of Studies. Randomised-
controlled trials are included for this study. 
Identified articles included humans and 
non-humans’ studies. Cross-sectional, case 
control, cohort, case report, case series, 
conference abstracts, expert opinion, and 
review papers are excluded. Articles with 
unavailable full-text, languages other than 




Figure 1. Structure (a,b) and Capabilities of 
eCD4-Ig in Neutralizing HIV Strains (c) and 
Enhancing ADCC (d)[16] 
Population. All subjects (humans or 
non-humans) challenged with infectious 
doses of HIV are included for this study. 
Intervention. Studies evaluating the 
efficacy of eCD4-Ig to neutralize HIV-
infected subjects are included. In addition, 
included studies also evaluate AAV-
eCD4-Ig to protect subjects from HIV 
infection. 
Comparison. Included studies 
compared HIV-infected subjects 
inoculated with and without eCD4-Ig to 
evaluate the efficacy at both therapeutic 
and preventive level.   
Outcome: The key findings of 
included studies are the number of subjects 
fully protected from HIV infection. 
 
 
eCD4-Ig as a Promising Broad and 
Potent Neutralizing Agent against HIV 
Infection 
Current trend in HIV/AIDS treatment 
is only limited to the suppression of viral 
load temporarily by using ART. The 
therapy developed for the last few decades 
focuses on targeting HIV Env by using 
bNAbs. Despite the promising potency and 
breadth, bNAbs still have a major 
drawback regarding of immunogenicity. 
Considering this, researchers have shifted 
their focus on using a more self-like 
molecule to target the conserved regions of 
HIV Env.[8,11]  
Recently, researchers have 
successfully engineered eCD4-Ig, a Fc-
fusion protein between domains 1 and 2 of 
human CD4 and IgG Fc with CCR5-
mimetic sulfopeptide attached in the 
carboxy terminus (Figure 1a). eCD4-Ig 
cooperatively binds to the CD4- and 
coreceptor-binding sites (Figure 1b) on all 
HIV subtypes hence its markedly superior 
potency and breadth.[12,16,17] 
eCD4-Ig eliminates HIV-infected cells 
through 2 main mechanisms: 
neutralization and antibody-dependent 
cell-mediated cytotoxicity (ADCC).[12,16,18] 
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neutralizes the highly diverse HIV isolates. 
According to an in vitro study by Gardner 
et al., eCD4-Ig neutralized 100% of HIV-
1, HIV-2, and SIV strains with IC50 and 
IC80 less than 1.5 μg/mL and 10 μg/mL, 
respectively (Figure 1c).[16] This finding is 
supported by another study done by Fetzer 
et al. which has shown the excellent 
potency of eCD4-Ig and its variants in 
neutralizing diverse HIV-1 isolates.[17]  
In addition of enhancing 
neutralization, CCR5-mimetic 
sulfopeptides ensure no viral escape and 
HIV-infection occurring in CD4-negative 
cells.[11,16,19,20] According to the study by 
Fellinger et al., eCD4-Ig was capable of 
altering HIV-1 Envs, hence making the 
viruses less infectious and more sensitive 
to antibodies present in the serum of HIV-
infected people.[20] Other studies done by 
Davis-Gardner et al. and Fetzer et al. also 
supported this finding. eCD4-Ig has the 
ability to expose the V3-loop of HIV Env 
hence its ability to enhance the potency of 
V3-loop antibodies, which are abundant 
but non-neutralizing in HIV-infected 
individuals.[18,21] 
The remarkable potency of eCD4-Ig 
also comes from its ability in mediating 
ADCC. An in vitro study by Davis-
Gardner et al. revealed that eCD4-Ig 
mediated killing of HIV-infected cells up 
to 10 times more efficiently by natural 
killer (NK) cells.[18] This finding is 
supported by another study by Gardner et 
al. It is revealed that eCD4-Ig enhanced 
ADCC activity by 30-40 times higher 
when tested against diverse HIV tropisms 
(Figure 1d).[16] Moreover, eCD4-Ig could 
alter the conformation of HIV Env so that 
pre-existing non-neutralizing antibodies in 
patients’ sera could bind to HIV Env and 
promote ADCC activity by 100-fold.[18] 
Besides having a remarkable 
therapeutic effect, eCD4-Ig is also proven 
to be capable of preventing HIV infection. 
An in vivo study by Gardner et al. revealed 
that eCD4-Ig fully protected humanized 
NOD/SCID/γc (NSG) mice infected with 
5x104 infectious units of HIVNL4-3. 
Complete protection was achieved at the 
concentration of 2–4 μg/mL and 
maintained up to 5 weeks after 
inoculation.[16] Moreover, the more self-
like structure of eCD4-Ig makes it less 
likely subjected to endogenous antibodies 
that can impair the efficacy. Even the 
additional CCR5-mimetic sulfopeptides do 
not elicit significant antibody 
responses.[12,16,19] These findings strongly 
suggested eCD4-Ig as a promising 
candidate for HIV vaccine development. 
 
eCD4-Ig Delivered by Adeno-associated 
Virus Vector (AAV-eCD4-Ig) as a 
Promising Novel Vaccine for HIV 
Infection 
Another important issue in developing 
an effective vaccine for HIV/AIDS is the 
use of an appropriate packaging system to 
ensure eCD4-Ig’s expression at protective 
and therapeutic levels. Previously, 
antibodies or antibody-like inhibitors were 
passively administered. However, this 
method prompted the need of repeated 
infusion which could lower patient’s 
compliance.[22,23] This approach is deemed 
inefficient and thus an alternative is 
needed to express biologically active 
molecules in a prolonged manner with a 
single inoculation. In this case, AAV 
vector appears to be a major breakthrough 
of this problem. 
Adeno-associated virus (AAV) is a 
small (20 nm), non-enveloped virus. It 
belongs to genus Dependoparvovirus, 
which in turn belonging to family 
Parvoviridae.[22] AAV vector-mediated 
gene transfer has gained a lot of attention 
as it is able to express desired-protein for 
the lifetime of the cell as long as the 
product is considered as self by one's 
immune system.[23] AAV particles also 
show high resistance to high temperature 
and widely-range pH, as well as stability 
after being stored for a long time.[22,23] 
Therefore, this paper strongly suggest the 
use of AAV to efficiently deliver eCD4-Ig 
(AAV-eCD4-Ig) both as a prevention and 
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Figure 2. AAV-eCD4-Ig Promotes Full Protection of Rhesus Macaques from SHIV-AD8 (a) and 
SIVmac239 Infection[12,16] 
AAV-eCD4-Ig can give full 
protection from HIV infection in non-
human studies. According to a study by 
Gardner et al. in 2015, AAV-eCD4-Ig 
completely protected four of four rhesus 
macaque from six escalating doses of 
simian-human immunodeficiency virus 
(SHIV-AD8) infection. A single 
administration of 2.5x1013 genomic copies 
(GCs) of AAV-eCD4-Ig was capable of 
maintaining stable eCD4-Ig expression 
between 17–77 μg/mL and giving robust 
protection for inoculated macaques up to 
40-week long (Figure 2a).[16] Another 
study by Gardner et al. in 2019 revealed 
that AAV-eCD4-Ig was capable of 
preventing SIVmac239 infection in four of 
four inoculated macaques with serum 
concentration as low as 3-18 μg/mL by the 
end of week-50 (Figure 2b).[12] These 
studies highlight the potential of AAV to 
achieve a long-term and stable transgene 
delivery in humans’ bodies, particularly in 
HIV-infected individuals. The delivery of 
eCD4-Ig is boosted to a point where its 
effectivity reaches beyond average. 
 
 
The extensive genetic diversity in HIV 
has been a challenge to develop an 
effective HIV vaccine. Recently, eCD4-Ig 
has been developed and proven to be the 
most potent and broad therapy at present. 
At a low concentration, eCD4-Ig is able to 
neutralize 100% of HIV-1, HIV-2, and 
SIV strains. It also mediates efficient 
killing by NK cells. In addition, the self-
like eCD4-Ig is less likely targeted by pre-
existing antibodies. This review revealed 
that one-time administration AAV-eCD4-
Ig fully protected test subjects from HIV 
infection for at least a year. Thus, AAV-
eCD4-Ig appears to have the potential to 




Further comprehensive studies should 
be done to assess the efficacy of AAV-
eCD4-Ig in vitro and in vivo, as it would 
serve as a foundation for future 
management of HIV/AIDS infection. 
Moreover, it is recommended that clinical 
trials are iniated to investigate the ability 
of AAV-eCD4-Ig in giving protection and 
treatment for HIV-infected patients. 
 
 
[1] CDC. HIV/AIDS [Internet]. Atlanta, 
GA: Center for Disease Control and 
Prevention; 2019 [cited 2019 Aug 
20]. Available from: 
https://www.cdc.gov/hiv  
[2] WHO. HIV/AIDS [Internet]. 
Geneva: World Health Organization; 










The Potential of eCD4-Ig, Delivered by Adeno-Associated Virus (AAV) Vector as a Novel Vaccine for HIV/AIDS Infection  
[3] UNAIDS. AIDSinfo [Internet]. 
Geneva: Joint United Nations 
Programme on HIV/AIDS; 2019 
[cited 2019 Aug 04]. Available from: 
https://aidsinfo.unaids.org/  
[4] Gama L, Koup RA. New-generation 
high-potency and designer 
antibodies: role in HIV-1 treatment. 
Annu Rev Med. 2018;69:14.1-14.11. 
doi: 10.1146/annurev-med-061016-
041032 
[5] Burton DR, Hangartner L. Broadly 
neutralizing antibodies to HIV and 
their role in vaccine design. Annu 
Rev Immunol. 2016;34:635–59. doi: 
10.1146/annurev-immunol-041015-
055515 
[6] Stephenson KE, Barouch DH. 
Broadly neutralizing antibodies for 
HIV eradication. Curr HIV/AIDS 
Rep. 2016;13:31–7. doi: 
10.1007/s11904-016-0299-7 
[7] Sahay B, Nguyen CQ, Yamamoto 
JK. Conserved HIV Epitopes for an 
Effective HIV Vaccine. J Clin Cell 
Immunol. 2017;8(4):518. doi: 
10.4172/2155-9899.1000518 
[8] Padte NN, Yu J, Huang Y, Ho DD. 
Engineering multi-specific 
antibodies against HIV-
1. Retrovirology. 2018;15(1):60. doi: 
10.1186/s12977-018-0439-9 
[9] Ferrari G, Haynes BF, Koenig S, 
Nordstorm JL, Margolis DM, 
Tomaras GD. Envelope-specific 
antibodies and antibody-derived 
molecules for treating and curing 
HIV infection. Nat Rev Drug 
Discov. 2016;15(12):823-34. doi: 
10.1038/nrd.2016.173 
[10] Hraber P, Seaman MS, Bailer RT, 
Mascola JR, Montefiori DC, et al. 
Prevalence of broadly neutralizing 
antibody responses during chronic 
HIV-1 infection. AIDS. 2014; 
28(2):163–69. doi: 
10.1097/QAD.0000000000000106 
[11] Gardner MR, Farzan M. Engineering 
antibody-like inhibitors to prevent 
and treat HIV-1 infection. Curr Opin 
HIV AIDS. 2017;12(3):294–301. 
doi: 
10.1097/COH.0000000000000367 
[12] Gardner MR, Fellinger CH, 
Kattenhorn LM, Davis-Gardner ME, 
Weber JA, Alfant B, et al. AAV-
delivered eCD4-Ig protects rhesus 
macaques from high-dose 
SIVmac239 challenges. Sci Transl 
Med. 2019 Jul 24;11(502). doi: 
10.1126/scitranslmed.aau5409 
[13] Gardner MR, Fetzer I, Kattenhorn 
LM, Davis-Gardner ME, Zhou AS, 
Alfant B, et al. Anti-drug Antibody 
Responses Impair Prophylaxis 
Mediated by AAV-Delivered HIV-1 
Broadly Neutralizing Antibodies. 
Mol Ther. 2019;27(3):650-60. doi: 
10.1016/j.ymthe.2019.01.004 
[14] Falkenhagen A, Joshi S. HIV Entry 
and Its Inhibition by Bifunctional 
Antiviral Proteins. Mol Ther Nucleic 
Acids. 2018;13:347–64. doi: 
10.1016/j.omtn.2018.09.003 
[15] Martinez-Navio JM, Fuchs SP, 
Pedreño-López S, Rakasz EG, Gao 
G, et al. Host anti-antibody 
responses following adeno-
associated virus-mediated delivery 
of antibodies against HIV and SIV in 
rhesus monkeys. Mol Ther. 
2016:24;76–86. doi: 
10.1038/mt.2015.191 
[16] Gardner MR, Kattenhorn LM, 
Kondur HR, et al. AAV-expressed 
eCD4-Ig provides durable protection 




[17] Fetzer I, Gardner MR, Davis-
Gardner ME, Prasad NR, Alfant B, 
Weber JA, et al. eCD4-Ig Variants 
That More Potently Neutralize HIV-
1. J Virol. 2018 Jun 
15;92(12):e02011-17. doi: 
10.1128/JVI.02011-17 
[18] Davis-Gardner ME, Gardner MR, 
Alfant B, Farzan M. eCD4-Ig 





The Potential of eCD4-Ig, Delivered by Adeno-Associated Virus (AAV) Vector as a Novel Vaccine for HIV/AIDS Infection  
from HIV-1-infected patients. PLoS 
Pathog. 2017;13(12):e1006786. doi: 
10.1371/journal.ppat.1006786 
[19] Quinlan BD, Joshi VR, Gardner MR, 
Ebrahimi KH, Farzan M. A double-
mimetic peptide efficiently 
neutralizes HIV-1 by bridging the 
CD4- and coreceptor-binding sites of 
gp120. J Virol. 2014;88(6):3353–8. 
doi: 10.1128/JVI.03800-13 
[20] Fellinger CH, Gardner MR, Weber 
JA, Alfant B, Zhou AS, Farzan M. 
eCD4-Ig Limits HIV-1 Escape More 
Effectively than CD4-Ig or a 
Broadly Neutralizing Antibody. J 
Virol. 2019 Jun 28;93(14). doi: 
10.1128/JVI.00443-19 
[21] Fetzer I, Davis-Gardner ME, 
Gardner MR, et al. A Coreceptor-
Mimetic Peptide Enhances the 
Potency of V3-Glycan Antibodies. J 
Virol. 2019;93(5):e01653-18. doi: 
10.1128/JVI.01653-18 
[22] Brady JM, Baltimore D, Balazs AB. 
Antibody gene transfer with adeno-
associated viral vectors as a method 
for HIV prevention. Immunol Rev. 
2017;275:324–33. doi: 
10.1111/imr.12478 
[23] Fuchs SP, Desrosiers RC. Promise 
and problems associated with the use 
of recombinant AAV for the delivery 
of anti-HIV antibodies. Mol Ther 
Methods Clin Dev. 2016;3:16068. 
doi: 10.1038/mtm.2016.68 
139
